International Poster Session 3 (JDDW)
November 5, 9:30–10:10, Room 16 (Kobe International Exhibition Hall No.3 Building Digital Poster Venue)
IP-14_H

The Prophylactic Effect of Entecavir and Tenofovir Disoproxil Fumarate on Hepatitis B Virus Flare Up in Hepatitis B Virus Patients with Cancer under Systemic Chemotherapy Travel Award

Kuang-Tsu Yang1
Co-authors: Yuan-Rong Li1, Yun-Da Li1, Wei-Chih Sun1, Sung-Shuo Kao1, Tzung-Jiun Tsai1, Kung-Hung Lin1, Huay-Min Wang1,2, Feng-Woei Tsay1,2, Hsien-Chung Yu1, Wei-Lun Tsai1,2, Wen-Chi Chen1,2
1
Division of Gastroenterology, Department of Medicine, Kaohsiung Veterans General Hospital
2
School of Medicine, National Yang-Ming University
Background
Prophylactic nucleos(t)ide analogues can alleviate the incidence of HBV reactivation in cancer patients undergoing chemotherapy. The aim of this research was to investigate the prophylactic effect of entecavir and tenofovir disoproxil fumarate.
Methods
During January 2011 and December 2020, we retrospectively enrolled cancer patients with seropositive HBsAg undergoing systemic chemotherapy to be treated with prophylactic entecavir and tenofovir disoproxil fumarate. We analyzed the incidence of HBV reactivation and the relevant clinical events of the patients. The risk factors of HBV reactivation were evaluated.
Results
350 patients (250 in entecavir group; 100 in tenofovir disoproxil fumarate group) were recruited. A trend of less incidence of HBV reactivation was found in the tenofovir disoproxil fumarate group than in the entecavir group (0.0% vs. 1.2%, P = 0.56). HBV reactivation was noticed in three patients taking entecavir. We found no significant risk factors of HBV reactivation in both groups.
Conclusions
Though entecavir had a trend of higher risk HBV reactivation than tenofovir, the prophylactic effect was statistically comparable and no severe clinical side effect happened.
Page Top